|
Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. The Company's new drug for benign prostatic hyperplasia (BPH) is in Phase 3 development.
Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. Nymox has a number of drugs in development for other indications such as E. coli infection, Alzheimer's disease, oncology, and infectious disease.
The Company offers NicAlert and TobacAlert tests for measuring tobacco product exposure, and AlzheimAlertTM, a test to aid in the diagnosis of Alzheimer's disease.
COMPANY WEBSITE
PRESENTATION
December 8th, 4:30 pm - Track Three
| 
